Pseudomonas Aeruginosa Infection Treatment Market with COVID-19 Impact Analysis, By Treatment Type (Monotherapy, Combination Therapy), By Drug (Cephalosporin, Aminoglycoside, Carbapenem, Monobactam, Others), By Route Of Administration (Nasal, Oral, Intravenous), By Distribution channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) By Country, and By Region Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
REPORT HIGHLIGHT
Pseudomonas aeruginosa infection treatment Market size was valued at USD 1,607.8 million in 2022, expanding at a CAGR of 6.8% from 2023 to 2030.
Pseudomonas aeruginosa infections are generally treated with antibiotics. However, due to the bacterium's ability to develop resistance, selecting appropriate antibiotics can be challenging. Pseudomonas aeruginosa has been known to develop resistance to various antibiotics, an including those commonly used to treat infections. However, certain antibiotics, such as polymyxins can still be effective against multidrug-resistant strains. Additionally, newer antibiotics and alternative therapies, such as bacteriophages and monoclonal antibodies, are being explored as potential treatment options for multidrug-resistant Pseudomonas aeruginosa infections.
Pseudomonas aeruginosa infection treatment Market- Market Dynamics
Increasing consumer awareness about Pseudomonas aeruginosa infection treatment to propel market demand
Increasing consumer awareness about Pseudomonas aeruginosa infection treatment can certainly have a positive impact on market demand for related products and services. increasing consumer awareness can also adoptive interest and investment in research and development efforts to combat Pseudomonas aeruginosa infections. Consumer awareness can also lead to increased demand for supportive care and patient engagement services. The demand for Pseudomonas aeruginosa infection treatment is driven by several factors, including the increasing prevalence of Pseudomonas aeruginosa infections, rising antibiotic resistance, and others. A retrospective analysis of Pseudomonas aeruginosa bloodstream infections identified that Pseudomonas aeruginosa (PA) is responsible for 10–15% of nosocomial infections worldwide.
Pseudomonas aeruginosa infection treatment Market- Key Insights
- As per the analysis shared by our research analyst, the global Pseudomonas aeruginosa infection treatment market is estimated to grow annually at a CAGR of around XX% over the forecast period (2023-2030)
- The Pseudomonas aeruginosa infection treatment industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
- Based on treatment segmentation, Combination Therapy was predicted to show maximum market share in the year 2022
- Based on drug type segmentation, Cephalosporin was the leading type in 2022
- Based on Route of Administration segmentation, Intravenous was the leading type in 2022
- Based on distribution channels segmentation, Hospitals was the leading type in 2022
- On the basis of region, North America was the leading revenue generator in 2022
Pseudomonas aeruginosa infection treatment Market- Segmentation Analysis:
The Global Pseudomonas aeruginosa infection treatment Market is segmented on the basis of treatment type, drug type, route of administration, distribution channel, and Region.
The market is divided into three categories based on treatment type: Monotherapy and Combination Therapy. Combination Therapy dominates the market. It is particularly in demand for the treatment of severe infections or infections caused by multidrug-resistant strains of Pseudomonas aeruginosa.
The market is divided into four categories based on drug type: Cephalosporin, Aminoglycoside, Carbapenem, Monobactam, and Others. Cephalosporin propels market growth, due to It can be effective against certain strains of Pseudomonas aeruginosa, it's worth mentioning that this bacterium is known to be inherently resistant to many cephalosporin’s, especially the first-generation cephalosporin’s.
The market is divided into three categories based on the Route of Administration: Nasal, Oral, and Intravenous. Intravenous dominates the market and is likely to maintain its dominance during the forecast period, due to the availability of drugs for the Intravenous route, and high occurrence in dosing.
The market is divided into three categories based on distribution channels: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Hospitals dominate the market and are likely to maintain their dominance during the forecast period. It plays a crucial role in diagnosing, treating, and preventing Pseudomonas aeruginosa infections. They have the resources, expertise, and patient population that necessitate effective treatment strategies for managing these infections.
Pseudomonas aeruginosa infection treatment Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the Pseudomonas aeruginosa infection treatment Market, due to a rise in the number of Pseudomonas aeruginosa infections. The elderly population may be particularly disposed to pseudomonad infection as a result of increased co-morbidities, the presence of invasive devices such as urinary catheters and feeding tubes, and polypharmacy that includes antibacterial, and immune compromise related to age. According to the center for disease control and Prevention, in 2017, multidrug-resistant Pseudomonas aeruginosa caused an estimated 32,600 infections among hospitalized patients and 2,700 estimated deaths in the United States. However, Asia Pacific and Europe are also expected to offer substantial growth opportunities for the Pseudomonas aeruginosa infection treatment market during the forecast period.
Pseudomonas aeruginosa infection treatment Market- Competitive Landscape:
The treatment market for Pseudomonas aeruginosa infections is competitive, with several pharmaceutical companies offering antibiotics and other therapeutic options to combat these infections. pharmaceutical companies involved in the development and marketing of antibiotics for Pseudomonas aeruginosa infections through a variety of channels, including corporate websites, e-commerce websites, retailers, distributors, and end consumers. Additionally, the ability to develop new antibiotics or combination therapies to address emerging drug resistance in Pseudomonas aeruginosa is crucial for maintaining competitiveness in this market. For example, in 2023, SPR-206 is under clinical development by Pfizer and is currently in Phase I for Pseudomonas aeruginosa Infections. According to Global Data, Phase I drugs for Pseudomonas aeruginosa Infections has a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.
Recent Developments:
Allergan plc recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental New Drug Application (sNDA) for AVYCAZ (ceftazidime and avibactam), seeking to expand the label to include the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI), in combination with metronidazole, in pediatric patients 3 months to less than 18 years of age.
Key features of the study:
- This proposed research study on Pseudomonas aeruginosa infection treatment market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
- The report provides the client the latest up-to-date and trending insights about the Pseudomonas aeruginosa infection treatment market.
- The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Pseudomonas aeruginosa infection treatment market
- The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Pseudomonas aeruginosa infection treatment market
- Impact of COVID-19 on Pseudomonas aeruginosa infection treatment market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Pseudomonas aeruginosa infection treatment market post-COVID will also be covered.
- In order to give the users of this report a comprehensive view on the Pseudomonas aeruginosa infection treatment market, we have also included competitive landscape and key innovator analysis for the Pseudomonas aeruginosa infection treatment market.
- The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
- The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Pseudomonas aeruginosa infection treatment market.
- In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
- The global Pseudomonas aeruginosa infection treatment market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET KEY PLAYERS
- Allergan
- Pfizer Inc.
- Merck & Co. Inc.
- AstraZeneca PLC
- Novartis AG
- Lupin Pharmaceuticals Inc.
- EnBiotix Inc
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Co.
- Humanigen Inc
- Other
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY TREATMENT TYPE
- Monotherapy
- Combination Therapy
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DRUG TYPE
- Cephalosporin
- Aminoglycoside
- Carbapenem
- Monobactam
- Others
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
- Nasal
- Oral
- Intravenous
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
GLOBAL PSEUDOMONAS AERUGINOSA INFECTION TREATMENT MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Pseudomonas aeruginosa infection treatment Market Overview
1.1. Study Scope
2. Executive Summary
2.1. Market Snippet
2.1.1. Pseudomonas aeruginosa infection treatment Market Snippet by Drug Type
2.1.2. Pseudomonas aeruginosa infection treatment Market Snippet by Route of Administration
2.1.3. Pseudomonas aeruginosa infection treatment Market Snippet by Distribution channels
2.1.4. Pseudomonas aeruginosa infection treatment Market Snippet by Country
2.1.5. Pseudomonas aeruginosa infection treatment Market Snippet by Region
2.2. Competitive Insights
3. Pseudomonas aeruginosa infection treatment Key Market Trends
3.1. Pseudomonas aeruginosa infection treatment Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Pseudomonas aeruginosa infection treatment Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Pseudomonas aeruginosa infection treatment Market Opportunities
3.4. Pseudomonas aeruginosa infection treatment Market Future Trends
4. Pseudomonas aeruginosa infection treatment Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Pseudomonas aeruginosa infection treatment Market: COVID-19 Impact Analysis
5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
5.2.1. Top Performing Segments
5.2.2. Marginal Growth Segments
5.2.3. Top Looser Segments
5.2.4. Marginal Loss Segments
6. Pseudomonas aeruginosa infection treatment Market Landscape
6.1. Pseudomonas aeruginosa infection treatment Market Share Analysis, 2022
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Pseudomonas aeruginosa infection treatment Market – By Drug Type
7.1. Overview
7.1.1. Segment Share Analysis, By Drug Type, 2022 & 2030 (%)
7.1.2. Cephalosporin
7.1.3. Aminoglycoside
7.1.4. Carbapenem
7.1.5. Monobactam
7.1.6. Others
8. Pseudomonas aeruginosa infection treatment Market – By Route of Administration
8.1. Overview
8.1.1. Segment Share Analysis, By Route of Administration, 2022 & 2030 (%)
8.1.2. Nasal
8.1.3. Oral
8.1.4. Intravenous
9. Pseudomonas aeruginosa infection treatment Market – By Distribution channels
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution channels, 2022 & 2030 (%)
9.1.2. Hospital Pharmacy
9.1.3. Retail Pharmacy
9.1.4. Online Pharmacy
10. Pseudomonas aeruginosa infection treatment Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
10.2. North America
10.2.1. Overview
10.2.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.2.4. North America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.2.5. North America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.2.6. North America Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.3.8. Italy
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.8.5. Italy Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.3.9. United Kingdom
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.9.5. United Kingdom Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.3.10. France
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.10.3. France Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.10.4. France Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.10.5. France Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.3.11. Russia
10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.11.4. Russia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.3.12. Netherlands
10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.12.4. Netherlands Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.3.13. Sweden
10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.3.14. Poland
10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.14.4. Poland Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.3.15. Rest of Europe
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Asia Pacific
10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.6. Asia Pacific Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.4.7. India
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.7.3. India Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.7.4. India Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.7.5. India Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.4.8. China
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.8.3. China Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.8.4. China Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.8.5. China Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.4.12. Thailand
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.12.5. Thailand Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.4.13. Indonesia
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.13.5. Indonesia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.5. Latin America
10.5.1. Overview
10.5.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Latin America
10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.5.4. Latin America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.6. Latin America Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.6. Middle East and Africa
10.6.1. Overview
10.6.2. Pseudomonas aeruginosa infection treatment Key Manufacturers in Middle East and Africa
10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.6. Middle East and Africa Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.6.8. United Arab Emirates
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2018 - 2030 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution channels, 2018 - 2030 (US$ Million)
11. Key Vendor Analysis- Pseudomonas aeruginosa infection treatment Industry
11.1. Competitive Dashboard
11.2. Company Profiles
11.2.1. Allergan
11.2.2. Pfizer Inc.
11.2.3. Merck & Co. Inc.
11.2.4. AstraZeneca PLC
11.2.5. Novartis AG
11.2.6. Lupin Pharmaceuticals Inc.
11.2.7. EnBiotix Inc
11.2.8. Teva Pharmaceutical Industries Ltd.
11.2.9. Bristol-Myers Squibb Co.
11.2.10. Humanigen Inc
11.2.11. Other
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
